Corporate Events

From July 1, 2026 to September 30, 2026, the company has repurchased 298,200 shares, representing 0.5% for ¥1,765.05 million. With this, the company has completed the repurchase of 384,900 shares, representing 0.64% for ¥2,245.85 million under the buyback announced on May 14, 2026.

Kaneka Corporation has announced a Fixed-Income Offering. Security Name: Straight Bonds due September 10, 2031 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Security Features: Unsecured

Kaneka Corporation provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of JPY 820,000 million, operating income of JPY 36,000 million, net income attributable to owners of parent of JPY 31,500 million and net income per share of JPY 523.04.

Kaneka Corporation provided second quarter 2027 dividend guidance of JPY 105.00 per share compared to JPY 80.00 per share paid a year ago. The company provided year-end dividend guidance of JPY 105.00 per share for the fiscal year ending March 31, 2027 compared to JPY 80.00 per share a year ago.

From May 14, 2026 to June 30, 2026, the company has repurchased 86,700 shares, representing 0.14% for ¥480.8 million. With this, the company has completed the repurchase of 86,700 shares, representing 0.14% for ¥480.8 million under the buyback announced on May 14, 2026.

Kaneka Corporation, ¥ 105., Cash Dividend, Sep-29-2026

Kaneka Corporation reported earnings results for the full year ended March 31, 2026. For the full year, the company reported sales was JPY 811,638 million compared to JPY 807,200 million a year ago. Net income was JPY 30,977 million compared to JPY 25,309 million a year ago. Basic earnings per share from continuing operations was JPY 501.26 compared to JPY 400.91 a year ago. Diluted earnings per share from continuing operations was JPY 499.47 compared to JPY 399.67 a year ago.

Kaneka Corporation announced that they will report Q1, 2027 results on Aug 13, 2026

Kaneka Corporation, Board Meeting, Jun 01, 2026. Agenda: To consider the Status of Share Repurchase.

Kaneka Corporation, Annual General Meeting, Jun 26, 2026, at 10:00 Tokyo Standard Time. Agenda: To consider report on the business report, consolidated financial statements and non consolidated financial statements for the 102nd fiscal year from April 1, 2025 to March 31, 2026; to consider report on the results of audit by the accounting auditor and the audit & supervisory board for the consolidated financial statements for the 102nd fiscal year from April 1, 2025 to March 31, 2026; to consider election of twelve members of the board; to consider election of one substitute audit & supervisory board member; to consider provision of bonus to members of the board; and to consider other matters.

The Board of Directors of Kaneka Corporation has authorized a buyback plan on May 14, 2026.

Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 1,400,000 shares, representing 2.32% of the outstanding shares for ¥7,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies that respond to changes in the business environment. The program will run until March 24, 2027. As of April 30, 2026, the company had 60,229,512 shares outstanding (excluding treasury stock) and 2,770,488 shares in treasury.

Kaneka Corporation, Board Meeting, May 14, 2026. Agenda: To consider Notice Regarding Determination of Matters Related to Repurchase of Treasury Stock and Cancellation of Treasury Stock.

Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026

The company closed its plan on March 17, 2026.

From January 1, 2026 to March 17, 2026, the company has repurchased 659,100 shares, representing 1.08% for ¥3,251.45 million. With this, the company has completed the repurchase of 2,708,100 shares, representing 4.37% for ¥11,999.73 million under the buyback announced on May 14, 2025.

Kaneka Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company revises net sales of JPY 800,000 million, operating income of JPY 34,000 million, net income attributable to owners of parent of JPY 31,500 million and net income per share of JPY 511.80.

Kaneka Corporation reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 598,278 million compared to JPY 603,048 million a year ago. Net income was JPY 18,440 million compared to JPY 17,736 million a year ago. Basic earnings per share from continuing operations was JPY 296.72 compared to JPY 280.67 a year ago. Diluted earnings per share from continuing operations was JPY 295.69 compared to JPY 279.81 a year ago.

Maezawa Industries, Inc. (TSE:6489) agreed to acquire remaining shares of Maezawa Kasei Industries Co., Ltd. (TSE:7925) from SMBC Nikko Securities Inc., Custody Bank of Japan, Ltd., Maezawa Kyuso Industries Co.,Ltd. (TSE:6485), The Master Trust Bank of Japan, Ltd. and others for ¥36.3 billion on December 16, 2025. The consideration consists of common equity of Maezawa Industries, Inc. to be issued for common equity of Maezawa Kasei Industries Co., Ltd. The transaction is subject to approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board and approval of offer by target shareholders. The deal has been approved by the board. Maezawa Industries, Inc. and MAEZAWA KASEI INDUSTRIES CO., LTD. have agreed to integrate their management by establishing MAEZAWA Holdings CO., LTD. (the “Joint Holding Company”), which will become the wholly owning parent company of the Companies through a joint share transfer scheduled to take effect on June 1, 2026. In connection with the Share Transfer, the Companies will become wholly owned subsidiaries of the Joint Holding Company. Accordingly, the shares of common stock of the Companies are scheduled to be delisted on May 28, 2026, prior to the listing of the shares of the Joint Holding Company. The Companies plan to apply for the initial listing of the shares of the Joint Holding Company on the Prime Market of Tokyo Stock Exchange, Inc. with the listing date scheduled for June 1, 2026. Both companies are expected to continue operating their businesses independently while maintaining their respective identities. Although the shares of both companies will be delisted, each company will remain as a wholly owned subsidiary of the new holding company and will not be dissolved. Kazumasa Miyagawa of Maezawa Industries will be appointed as Representative Director and President. Satoru Tanaka of MAEZAWA KASEI INDUSTIRIES will be appointed as Representative Director and Executive Vice President. Terutaka Inoue of Maezawa Industries and Masahiro Ito of MAEZAWA KASEI INDUSTIRIES will be appointed as Audit and Supervisory Committee Member. Takashi Hosoda of Maezawa Industries and Mami Kato, Tatsuya Kato of MAEZAWA KASEI INDUSTIRIES will be appointed as Audit and Supervisory Committee Member (Outside Director) of the new holding company. Through a joint share transfer (the “Share Transfer”) scheduled to take effect on June 1, 2026. Kazumasa Miyagawa, Satoru Tanaka, Terutaka Inoue, Masahiro Ito, Takashi Hosoda, Mami Kato and Tatsuya Kato these candidates to assume office as representatives or officers. Daiwa Securities Co. Ltd. acted as financial advisor for Maezawa Kasei Industries Co., Ltd. Miyake & Partners acted as legal advisor for Maezawa Kasei Industries Co., Ltd. Deloitte Tohmatsu Financial Advisory LLC, Accounting & Auditing Arm acted as accountant for Maezawa Kasei Industries Co., Ltd. STREAM Co., Ltd. acted as accountant for Maezawa Industries, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for Maezawa Industries, Inc. Kensei Law Offices acted as legal advisor for Maezawa Industries, Inc.

Kaneka Corporation expected to report Fiscal Year 2026 results on May 13, 2026. This event was calculated by S&P Global (Created on January 10, 2026).

From October 1, 2025 to December 31, 2025, the company has repurchased 564,000 shares, representing 0.92% for ¥2,397.45 million. With this, the company has completed the repurchase of 2,049,000 shares, representing 3.29% for ¥8,748.28 million under the buyback announced on May 14, 2025.

Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026

Kaneka Corporation, ¥ 80.0, Cash Dividend, Mar-30-2026

Kaneka Corporation expected to report Q3 2026 results on February 6, 2026. This event was calculated by S&P Global (Created on November 12, 2025).

Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.

Kaneka Corporation announced dividend of JPY 80.00 per share for the second quarter ended September 30, 2025 against JPY 60.00 per share a year ago. Scheduled date of dividend distribution: December 5, 2025.

Kaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.